Interim report for Q1 2020
The development of the Covid-19 pandemic has painfully highlighted the urgent need for infection prevention. This has led to an increased interest in Bactiguard and generated strong sales from mid-March. Total revenues increased by more than 40 percent in the quarter and EBITDA doubled, generating an EBITDA margin of 30 percent and a positive net result.First quarter (January-March 2020) · Revenues amounted to SEK 48,1 (33,9) million and increased by 42% (adjusted for currency 36%). · EBITDA amounted to SEK 14,4 (7,2) million with an EBITDA-margin of 30% (21%). · Operating profit